BG
CHRS icon

Bellevue Group’s Coherus Oncology CHRS Stock Holding History

Bellevue Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-149,000
Closed -$2.59M – 223
2020
Q4 		$2.59M Sell
149,000
-1,254,400
-89% -$22.3M 0.03% 139
2020
Q3 		$25.7M Buy
1,403,400
+246,000
+21% +$4.58M 0.36% 77
2020
Q2 		$20.7M Buy
1,157,400
+1,108,900
+2,286% +$18.8M 0.29% 78
2020
Q1 		$787K Sell
48,500
-100,000
-67% -$1.85M 0.02% 146
2019
Q4 		$2.67M Sell
148,500
-52,935
-26% -$976K 0.04% 124
2019
Q3 		$4.08M Buy
201,435
+34,800
+21% +$695K 0.08% 115
2019
Q2 		$3.68M Sell
166,635
-150,500
-47% -$2.61M 0.06% 115
2019
Q1 		$4.33M Sell
317,135
-41,800
-12% -$558K 0.24% 81
2018
Q4 		$3.25M Buy
358,935
+143,000
+66% +$1.65M 0.21% 85
2018
Q3 		$3.56M Buy
215,935
+18,100
+9% +$321K 0.23% 88
2018
Q2 		$2.77M Buy
197,835
+47,835
+32% +$685K 0.24% 77
2018
Q1 		$1.66M Hold
150,000
– – 0.16% 88
2017
Q4 		$1.32M Buy
+150,000
New +$1.61M 0.14% 98
2017
Q2 		– Sell
-175,000
Closed -$3.7M – 135
2017
Q1 		$3.7M Hold
175,000
– – 0.49% 58
2016
Q4 		$4.93M Sell
175,000
-27,000
-13% -$756K 1.01% 33
2016
Q3 		$5.41M Sell
202,000
-102,000
-34% -$2.78M 0.98% 38
2016
Q2 		$5.13M Buy
304,000
+17,000
+6% +$319K 0.97% 37
2016
Q1 		$6.09M Buy
+287,000
New +$4.7M 1.11% 30

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bellevue Group's CHRS Position: Q1 2021 in Review

Bellevue Group sold out of Coherus Oncology (CHRS) in Q1 2021, closing a stake of 149,000 shares — an estimated $2.59M sold.

Bellevue Group first reported a position in CHRS in Q1 2016 and held it in 18 quarters. The position peaked at $25.7M in Q3 2020. 205 funds tracked by Wall St. Rank hold CHRS as of Q1 2021.

  • Bellevue Group reported no remaining Coherus Oncology position as of Q1 2021 after selling out during the quarter.
  • Bellevue Group sold 149,000 Coherus Oncology shares in Q1 2021, an estimated $2.59M.
  • Bellevue Group first reported a position in Coherus Oncology in Q1 2016 and held it in 18 quarters.
  • Bellevue Group's Coherus Oncology position peaked at $25.7M in Q3 2020.
  • 205 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2021.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.